

---

## REFERENCES

- 1 Alwan A, editor. *Global status report on noncommunicable diseases 2010*. Geneva: World Health Organization; 2011.
- 2 Mukherjee S. *The emperor of all maladies: a biography of cancer*. New York: Simon & Schuster; 2010.
- 3 Watson J. *Open Biol* 2013;**3**:120144.
- 4 Nelson SM, Ferguson LR, Denny WA. *Cell Chromosome* 2004;**3**:2.
- 5 Hanahan G, Weinberg RA. *Cell* 2000;**100**:57.
- 6 Bissell MJ, Radisky D. *Nature Rev Cancer* 2001;**1**:46.
- 7 Hanahan G, Weinberg RA. *Cell* 2011;**144**:646.
- 8 Lebowitz P. *J Clin Oncol* 1983;**1**:657.
- 9 (a) Shih Ch, Weinberg RA. *Cell* 1982;**29**:161; (b) Santos E, Tronick SR, Aaronson SA, Pulciani S, Barbacid M. *Nature* 1982;**298**:343.
- 10 (a) Yanagi Y, Yoshikai Y, Leggett K, Clark SP, Aleksander I, Mak TW. *Nature* 1984;**308**:145; (b) Williams AF. *Nature* 1984;**308**:108.
- 11 (a) Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. *N Engl J Med* 2010;**363**:711; (b) Robert C, Thomas L, Bondarenko I, O'Day S, Garbe C, Lebbe C, et al. *N Engl J Med* 2011;**364**:2517.
- 12 Couzin-Frankel J. *Science* 2013;**342**:1432.
- 13 Relling MV, Hancock M, Rivera GK, Sandlund JT, Ribeiro RC, Krynetski EY, et al. *J Natl Cancer Inst* 1999;**91**:2001.
- 14 Innocenti F, Schilsky RL. *Dis Model Mech* 2009;**2**:426.
- 15 Yong WP, Soo R, Innocenti F. In: Neidle S, editor. *Cancer drug design and discovery*. 2nd ed. New York: Academic Press; 2014.
- 16 The Cancer Genome Atlas Network. *Nature* 2012;**490**:61.
- 17 Gerlinger M, Rowan AJ, Horswell S, Larkin J, Endesfelder D, Gronroos E, et al. *N Engl J Med* 2012;**366**:883.
- 18 Yong E. *Nature* 2014;**511**:524.
- 19 Sorenson GD, Pribish DM, Valone FH, Memoli VA, Bzik DJ, Yao SL. *Cancer Epidemiol Biomarkers Prev* 1994;**3**:67.
- 20 Newman AM, Bratman SV, To J, Wynne JF, Eclow NC, Modlin LA, et al. *Nat Med* 2014;**20**:548.
- 21 Esserman LJ, Thompson Jr IM, Reid B. *JAMA* 2013;**310**:797.
- 22 Neidle S, Thurston DE. *Nature Rev Cancer* 2005;**5**:285.
- 23 Lathrop AE, Loeb L. *J Cancer Res* 1916;**1**:1.
- 24 Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, et al. *J Natl Cancer Inst* 1998;**90**:1371.
- 25 Goss PE, Ingle JN, Alés-Martínez JE, Cheung AM, Chlebowski RT, Wactawski-Wende J, et al. *N Engl J Med* 2011;**364**:2381.
- 26 Eckhardt S. *Curr Med Chem Anticancer Agents* 2002;**2**:419.
- 27 <http://www.sanger.ac.uk/genetics/CGP/Census>.
- 28 Marchini S, Brogginini M. *Curr Med Chem Anticancer Agents* 2004;**4**:247.
- 29 Hurley LH. *Nature Rev Cancer* 2002;**2**:188.
- 30 Gago F. *Methods* 1998;**14**:277.
- 31 Longley DB, Harkin DP, Johnston PG. *Nature Rev Cancer* 2003;**3**:330.
- 32 Bradbury RH, editor. *Top Med Chem* 2007;**1**.
- 33 Sliwkowski MX, Lofgren JA, Lewis GD, Hotaling TE, Fendly BM, Fox JA. *Semin Oncol* 1999;**26**:60.
- 34 Capdeville R, Buchdunger E, Zimmermann J, Matter A. *Nature Rev Drug Discov* 2002;**1**:493.
- 35 Atkins JH, Gershell LJ. *Nature Rev Drug Discov* 2002;**1**:491.